Clinical Outcomes of Fixed Versus As-Needed Use of Artificial Tears in Dry Eye Disease: A 6-Week, Observer-Masked Phase 4 Clinical Trial | Zendy

Penny A. Asbell | Zendy; Algis J. Vingrys | Zendy; Jacqueline Tan | Zendy; Abayomi Ogundele | Zendy; Laura E. Downie | Zendy; Gary Jerkins | Zendy; Lee Shettle | Zendy

Open Access

Clinical Outcomes of Fixed Versus As-Needed Use of Artificial Tears in Dry Eye Disease: A 6-Week, Observer-Masked Phase 4 Clinical Trial

Author(s) -

Penny A. Asbell,

Algis J. Vingrys,

Jacqueline Tan,

Abayomi Ogundele,

Laura E. Downie,

Gary Jerkins,

Lee Shettle

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.17-23733

Subject(s) - medicine , dosing , artificial tears , confidence interval , adverse effect , randomized controlled trial , surgery , incidence (geometry) , peg ratio , physics , finance , optics , economics

To evaluate the clinical effects of using fixed (four times daily [QID]) versus as-needed (PRN) dosing of an artificial tear product (polyethylene glycol/propylene glycol [PEG/PG]; Systane Ultra) in individuals with dry eye disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research